Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model
Robert Polten1, Ivana Kutle1, Jan Lennart Stalp1,2
1Institute of Experimental Hematology, Hannover Medical School, 30625, Hannover, Germany.
Abstract:
Genetic profiling of a new HPV-negative cervical cancer model identified pathogenic variants in genes implicated in oncogenic signaling, cell cycle regulation, and DNA damage repair pathways, including homologous recombination, non-homologous end-joining, and mismatch repair. Deficiencies in BRCA2, RAD51 and MLH1 were among these actionable targets. The newly described cervical cancer model revealed sensitivity towards the PARP inhibitor olaparib, which was further augmented upon combination with platinum-based chemotherapeutics. In contrast, BRCA1/2-proficient cervical cancer cells exhibited greater resistance to these strategies. This study highlights the potential of in-depth genetic analysis to identify genetic susceptibilities to guide personalized medicine approaches.
Insights
New cervical cancer models reveal genetic vulnerabilities in DNA repair. Targeting these with PARP inhibitors like olaparib shows promise for personalized treatment, especially when combined with chemotherapy.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Cervical cancer treatment often faces challenges due to tumor heterogeneity.
- Understanding the genetic landscape of HPV-negative cervical cancer is crucial for developing targeted therapies.
Purpose of the Study:
- To genetically profile a novel HPV-negative cervical cancer model.
- To identify actionable targets and therapeutic sensitivities.
Main Methods:
- Genetic profiling of a new cervical cancer model.
- Assessment of sensitivity to PARP inhibitors (olaparib) and platinum-based chemotherapeutics.
- Comparison with BRCA1/2-proficient cells.
Main Results:
- Identified pathogenic variants in oncogenic signaling, cell cycle, and DNA repair pathways (homologous recombination, non-homologous end-joining, mismatch repair).
- Found deficiencies in BRCA2, RAD51, and MLH1 as actionable targets.
- Demonstrated sensitivity of the model to olaparib, enhanced by combination therapy.
- Observed resistance in BRCA1/2-proficient cells.
Conclusions:
- In-depth genetic analysis can uncover susceptibilities in cervical cancer.
- Targeting DNA repair deficiencies with PARP inhibitors and chemotherapy offers a personalized medicine strategy.
- This model provides a platform for evaluating novel therapeutic combinations.
More Related Videos
06:59Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
Published on: March 31, 2022
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020